Cantor Fitzgerald set a $2.00 price objective on Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a report published on Tuesday morning. The firm currently has a hold rating on the biotechnology company’s stock.
ARWR has been the subject of several other research reports. ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a strong sell rating to a sell rating in a research report on Thursday, August 24th. William Blair raised shares of Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a report on Monday, September 18th. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, December 2nd. Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 price objective for the company in a report on Monday, November 27th. Finally, Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $3.17.
Arrowhead Pharmaceuticals (ARWR) opened at $3.55 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.84 and a current ratio of 3.84. Arrowhead Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $4.54.
ILLEGAL ACTIVITY NOTICE: “Arrowhead Pharmaceuticals (ARWR) Given a $2.00 Price Target at Cantor Fitzgerald” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/13/arrowhead-pharmaceuticals-arwr-given-a-2-00-price-target-at-cantor-fitzgerald.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
What are top analysts saying about Arrowhead Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Arrowhead Pharmaceuticals and related companies.